3.750GBP+1.63%Mkt Cap: 30.01M $P/E: —1d ago
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the Unite…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap30.01M $
Enterprise Value22.45M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-2.32M $
Revenue/Share—
Last Price3.750 GBP
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees7
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB0033711010
Valuation
P/E (Trailing)—
P/E (Forward)-0.01
PEG—
EV/EBITDA-7.00
EV/Revenue—
P/S—
P/B39.85
EPS (TTM)0.00
EPS (Forward)-3.39
52W Range
1.49013% of range19.40
52W High19.40 GBP
52W Low1.490 GBP
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-263.18%
ROA-96.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.04M $
CapEx (TTM)2.12K $
FCF Margin—
FCF Yield-6.79%
Net Debt-1.73M $
Net Debt/EBITDA0.54
Balance Sheet
Debt/Equity—
Current Ratio1.52
Quick Ratio1.46
Book Value/Sh0.0010 GBP
Cash/Share0.0030 GBP
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBP
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.623.91M
Float486.38M
Insiders4.97%
Institutions19.38%
Technical
SMA 504.042 (-7.2%)
SMA 2005.530 (-32.2%)
Beta3.01
S&P 52W Chg18.16%
Avg Vol (30d)1.50M
Avg Vol (10d)1.84M
Technical Indicators
RSI (14)47.2
MACD-0.0924
MACD Signal-0.0651
MACD Hist.-0.0273
BB Upper4.673 GBP
BB Middle3.998 GBP
BB Lower3.322 GBP
BB Width33.78%
ATR (14)0.7210 GBP
Vol Ratio (20d)0.38x